Indaptus Historical Income Statement

INDP Stock

USD 7.30 0.86 10.54%

Historical analysis of Indaptus Therapeutics income statement accounts such as Cost Of Revenue of 698 or Total Operating Expenses of 14.2 M can show how well Indaptus Therapeutics performed in making a profits. Evaluating Indaptus Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Indaptus Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Indaptus Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Indaptus Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Build AI portfolio with Indaptus Stock

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Indaptus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Indaptus Stock, please use our How to Invest in Indaptus Therapeutics guide.

About Indaptus Income Statement Analysis

Indaptus Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Indaptus Therapeutics shareholders. The income statement also shows Indaptus investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Indaptus Therapeutics Income Statement Chart

At this time, Indaptus Therapeutics' Research Development is relatively stable compared to the past year. As of 08/04/2025, Total Other Income Expense Net is likely to grow to about 360.9 K, though Other Operating Expenses is likely to grow to (14.6 M).

Research Development Cost Of Revenue Total Operating Expenses Selling General Administrative

Cost Of Revenue

Cost of Revenue is found on Indaptus Therapeutics income statement and represents the costs associated with goods and services Indaptus Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Indaptus Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Indaptus Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Indaptus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

To learn how to invest in Indaptus Stock, please use our How to Invest in Indaptus Therapeutics guide.At this time, Indaptus Therapeutics' Research Development is relatively stable compared to the past year. As of 08/04/2025, Total Other Income Expense Net is likely to grow to about 360.9 K, though Other Operating Expenses is likely to grow to (14.6 M).

	2022	2023	2024	2025 (projected)
Total Operating Expenses	14.9M	16.4M	15.4M	14.2M
Cost Of Revenue	1.8K	1.3K	735.0	698.25

Total Operating Expenses Cost Of Revenue

Indaptus Therapeutics income statement Correlations

	Depreciation And Amortization	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Net Interest Income	Interest Income	Net Income From Continuing Ops	Reconciled Depreciation
Depreciation And Amortization		-1.0	0.64	-0.46	-0.47	0.56	-0.45	1.0	0.44	-0.47	-0.33	-0.48	0.57	-0.67	-0.77	0.9	-0.67	-0.67	0.74	-0.52
Gross Profit	-1.0		-0.64	0.46	0.47	-0.56	0.45	-1.0	-0.44	0.47	0.33	0.48	-0.57	0.67	0.77	-0.9	0.67	0.67	-0.74	0.52
Other Operating Expenses	0.64	-0.64		-0.73	-0.74	0.78	-0.73	0.64	0.74	-0.73	-0.41	-0.73	0.47	-0.45	-0.35	0.45	-0.45	-0.45	0.44	0.07
Operating Income	-0.46	0.46	-0.73		0.98	-0.98	0.98	-0.46	-1.0	0.98	0.46	0.98	0.04	-0.06	0.01	-0.16	-0.05	-0.05	0.02	0.06
Ebit	-0.47	0.47	-0.74	0.98		-0.96	1.0	-0.47	-0.98	1.0	0.63	1.0	0.0	-0.02	0.05	-0.18	-0.01	-0.01	-0.01	0.07
Research Development	0.56	-0.56	0.78	-0.98	-0.96		-0.96	0.56	0.98	-0.96	-0.46	-0.96	0.09	-0.1	-0.19	0.29	-0.11	-0.11	0.15	-0.18
Ebitda	-0.45	0.45	-0.73	0.98	1.0	-0.96		-0.45	-0.98	1.0	0.63	1.0	0.02	-0.04	0.03	-0.15	-0.03	-0.03	0.0	0.05
Cost Of Revenue	1.0	-1.0	0.64	-0.46	-0.47	0.56	-0.45		0.44	-0.47	-0.33	-0.48	0.57	-0.67	-0.77	0.9	-0.67	-0.67	0.74	-0.52
Total Operating Expenses	0.44	-0.44	0.74	-1.0	-0.98	0.98	-0.98	0.44		-0.98	-0.46	-0.98	-0.04	0.06	0.0	0.14	0.05	0.05	-0.03	-0.04
Income Before Tax	-0.47	0.47	-0.73	0.98	1.0	-0.96	1.0	-0.47	-0.98		0.63	1.0	-0.01	-0.01	0.06	-0.18	-0.01	-0.01	-0.02	0.08
Total Other Income Expense Net	-0.33	0.33	-0.41	0.46	0.63	-0.46	0.63	-0.33	-0.46	0.63		0.64	-0.18	0.18	0.2	-0.2	0.18	0.18	-0.19	0.13
Net Income	-0.48	0.48	-0.73	0.98	1.0	-0.96	1.0	-0.48	-0.98	1.0	0.64		-0.01	0.0	0.06	-0.19	0.0	0.0	-0.03	0.09
Income Tax Expense	0.57	-0.57	0.47	0.04	0.0	0.09	0.02	0.57	-0.04	-0.01	-0.18	-0.01		-0.86	-0.75	0.63	-0.86	-0.86	0.85	-0.09
Interest Expense	-0.67	0.67	-0.45	-0.06	-0.02	-0.1	-0.04	-0.67	0.06	-0.01	0.18	0.0	-0.86		0.9	-0.74	1.0	1.0	-0.98	0.42
Selling General Administrative	-0.77	0.77	-0.35	0.01	0.05	-0.19	0.03	-0.77	0.0	0.06	0.2	0.06	-0.75	0.9		-0.86	0.9	0.9	-0.96	0.67
Selling And Marketing Expenses	0.9	-0.9	0.45	-0.16	-0.18	0.29	-0.15	0.9	0.14	-0.18	-0.2	-0.19	0.63	-0.74	-0.86		-0.74	-0.74	0.82	-0.57
Net Interest Income	-0.67	0.67	-0.45	-0.05	-0.01	-0.11	-0.03	-0.67	0.05	-0.01	0.18	0.0	-0.86	1.0	0.9	-0.74		1.0	-0.98	0.42
Interest Income	-0.67	0.67	-0.45	-0.05	-0.01	-0.11	-0.03	-0.67	0.05	-0.01	0.18	0.0	-0.86	1.0	0.9	-0.74	1.0		-0.98	0.42
Net Income From Continuing Ops	0.74	-0.74	0.44	0.02	-0.01	0.15	0.0	0.74	-0.03	-0.02	-0.19	-0.03	0.85	-0.98	-0.96	0.82	-0.98	-0.98		-0.54
Reconciled Depreciation	-0.52	0.52	0.07	0.06	0.07	-0.18	0.05	-0.52	-0.04	0.08	0.13	0.09	-0.09	0.42	0.67	-0.57	0.42	0.42	-0.54

Click cells to compare fundamentals

Indaptus Therapeutics Account Relationship Matchups

Indaptus Therapeutics income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	852.0	1.4K	1.8K	1.3K	735.0	698.25
Gross Profit	(852.0)	(1.4K)	(1.8K)	(1.3K)	(1.5K)	(1.6K)
Other Operating Expenses	3.6M	7.7M	14.9M	16.4M	(15.4M)	(14.6M)
Operating Income	(3.6M)	(7.7M)	(14.9M)	(16.4M)	(15.4M)	(16.1M)
Ebit	(3.6M)	(7.7M)	(14.9M)	(16.4M)	(15.0M)	(15.8M)
Research Development	2.7M	2.5M	6.3M	7.6M	7.3M	9.6M
Ebitda	(3.6M)	(7.7M)	(14.9M)	(16.4M)	(15.0M)	(15.8M)
Cost Of Revenue	852.0	1.4K	1.8K	1.3K	735.0	698.25
Total Operating Expenses	3.6M	7.7M	14.9M	16.4M	15.4M	14.2M
Income Before Tax	(3.6M)	(7.7M)	(14.3M)	(15.4M)	(15.0M)	(15.8M)
Total Other Income Expense Net	15.1K	17.7K	588.1K	955.0K	343.7K	360.9K
Net Income	(3.6M)	(7.7M)	(13.7M)	(15.4M)	(15.0M)	(15.8M)
Income Tax Expense	(15.1K)	(17.7K)	(588.1K)	(16.4M)	(14.7M)	(14.0M)
Interest Expense	15K	15.1K	17.7K	588.1K	676.3K	710.1K
Selling General Administrative	944.2K	5.2M	8.6M	8.7M	8.1M	5.9M

Additional Tools for Indaptus Stock Analysis

When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Indaptus Historical Income Statement

About Indaptus Income Statement Analysis

Indaptus Therapeutics Income Statement Chart

Cost Of Revenue

Total Operating Expenses

Indaptus Therapeutics income statement Correlations

Indaptus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Indaptus Therapeutics income statement Accounts

Additional Tools for Indaptus Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cost Of Revenue	+ 1.0	Depreciation And Amortization
Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebit
Net Income	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebitda
Net Income	+ 1.0	Ebitda

Total Operating Expenses	- 1.0	Operating Income
Cost Of Revenue	- 1.0	Gross Profit
Gross Profit	- 1.0	Depreciation And Amortization
Net Income From Continuing Ops	- 0.98	Interest Income
Net Income From Continuing Ops	- 0.98	Net Interest Income
Net Income From Continuing Ops	- 0.98	Interest Expense